$FATE
Fate Therapeutics Inc Stock $fate

$fate Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000095017023017175 Filed on May 03, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$933.0K	$58.98M	$18.41M
YoY Change	-94.97%	220.3%	65.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$22.62M	$21.94M	$20.74M
YoY Change	11.16%	5.79%	65.94%
% of Gross Profit
Research & Development	$40.88M	$65.63M	$72.14M
YoY Change	-49.73%	-9.02%	60.84%
% of Gross Profit
Depreciation & Amortization	$4.466M	$4.191M	$2.761M
YoY Change	50.78%	51.79%	187.9%
% of Gross Profit
Operating Expenses	$63.50M	$87.57M	$92.88M
YoY Change	-37.54%	-5.72%	61.95%
Operating Profit	-$62.57M	-$28.59M	-$74.47M
YoY Change	-24.72%	-61.6%	61.15%
Interest Expense	$4.774M	$5.412M	$8.777M
YoY Change	-28.08%	-38.34%	683.66%
% of Operating Profit
Other Income/Expense, Net	$5.036M	$9.711M	$8.777M
YoY Change	-28.1%	10.64%	682.96%
Pretax Income	-$52.76M	-$18.88M	-$65.69M
YoY Change	-30.68%	-71.26%	45.69%
Income Tax
% Of Pretax Income
Net Earnings	-$52.76M	-$18.88M	-$65.69M
YoY Change	-30.68%	-71.26%	45.69%
Net Earnings / Revenue	-5654.34%	-32.01%	-356.74%
Basic Earnings Per Share	-$0.54	-$0.19	-$0.68
Diluted Earnings Per Share	-$0.54	-$0.19	-$681.8K
COMMON SHARES
Basic Shares Outstanding	98.38M	98.16M	96.43M
Diluted Shares Outstanding	98.40M	98.05M	96.34M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$377.9M	$408.9M	$573.8M
YoY Change	-33.56%	-28.74%	-27.38%
Cash & Equivalents	$46.80M	$42.02M	$64.74M
Short-Term Investments	$331.1M	$366.9M	$509.0M
Other Short-Term Assets	$11.41M	$15.49M	$11.45M
YoY Change	-33.57%	35.25%	59.07%
Inventory
Prepaid Expenses
Receivables	$2.833M	$13.50M	$13.85M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$392.2M	$437.9M	$599.1M
YoY Change	-34.54%	-26.91%	-25.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$170.1M	$108.6M	$97.86M
YoY Change	64.93%	10.97%	-15.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.291M	$3.912M	$67.94M
YoY Change	-38.86%	-94.24%	-30.88%
Other Assets	$15.21M	$33.00K	$33.00K
YoY Change	45990.91%	0.0%	-99.78%
Total Long-Term Assets	$192.6M	$192.4M	$259.3M
YoY Change	-7.37%	-25.78%	7.29%
TOTAL ASSETS
Total Short-Term Assets	$392.2M	$437.9M	$599.1M
Total Long-Term Assets	$192.6M	$192.4M	$259.3M
Total Assets	$584.8M	$630.3M	$858.4M
YoY Change	-27.54%	-26.57%	-17.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.506M	$9.855M	$11.44M
YoY Change	-10.86%	-13.89%	27.16%
Accrued Expenses	$35.26M	$31.51M	$35.11M
YoY Change	-13.0%	-10.24%	67.74%
Deferred Revenue	$1.929M	$1.738M	$22.58M
YoY Change	-94.27%	-92.3%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.69M	$48.65M	$77.91M
YoY Change	-51.17%	-37.56%	-17.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$102.3M	$104.2M	$147.1M
YoY Change	-24.25%	-29.15%	-8.81%
Total Long-Term Liabilities	$102.3M	$104.2M	$147.1M
YoY Change	-24.25%	-29.15%	-8.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.69M	$48.65M	$77.91M
Total Long-Term Liabilities	$102.3M	$104.2M	$147.1M
Total Liabilities	$147.0M	$152.9M	$225.0M
YoY Change	-35.12%	-32.06%	-12.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.122B	-$1.070B	-$834.8M
YoY Change	23.23%	28.14%
Common Stock	$99.00K	$98.00K	$97.00K
YoY Change	2.06%	1.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$437.8M	$477.5M	$633.4M
YoY Change
Total Liabilities & Shareholders Equity	$584.8M	$630.3M	$858.4M
YoY Change	-27.54%	-26.57%	-17.94%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$52.76M	-$18.88M	-$65.69M
YoY Change	-30.68%	-71.26%	45.69%
Depreciation, Depletion And Amortization	$4.466M	$4.191M	$2.761M
YoY Change	50.78%	51.79%	187.9%
Cash From Operating Activities	-$28.49M	-$28.86M	-$64.61M
YoY Change	-46.4%	-55.33%	138.46%
INVESTING ACTIVITIES
Capital Expenditures	$2.199M	$3.208M	$10.08M
YoY Change	-121.71%	-68.19%	153.3%
Acquisitions
YoY Change
Other Investing Activities	$35.37M	$12.55M	$3.058M
YoY Change	-29.85%	310.33%	-100.65%
Cash From Investing Activities	$33.17M	$9.340M	-$7.026M
YoY Change	-17.67%	-232.93%	-98.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	58.00K	207.0K	2.797M
YoY Change	-98.3%	-92.6%	-99.36%
NET CHANGE
Cash From Operating Activities	-28.49M	-28.86M	-64.61M
Cash From Investing Activities	33.17M	9.340M	-7.026M
Cash From Financing Activities	58.00K	207.0K	2.797M
Net Change In Cash	4.732M	-19.31M	-68.84M
YoY Change	-149.99%	-71.95%	12.98%
FREE CASH FLOW
Cash From Operating Activities	-$28.49M	-$28.86M	-$64.61M
Capital Expenditures	$2.199M	$3.208M	$10.08M
Free Cash Flow	-$30.69M	-$32.07M	-$74.70M
YoY Change	-28.67%	-57.07%	140.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9340000
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001434316
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
CY2022Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36076
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	FATE THERAPEUTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	65-1311552
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	12278 Scripps Summit Drive
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92131
CY2023Q1	dei	City Area Code CityAreaCode	858
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	875-1800
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q1	dei	Trading Symbol TradingSymbol	FATE
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	98384456
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42020000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61333000
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13500000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	38480000
CY2023Q1	fate	Short Term Investments And Related Maturity Receivables ShortTermInvestmentsAndRelatedMaturityReceivables	366878000
CY2022Q4	fate	Short Term Investments And Related Maturity Receivables ShortTermInvestmentsAndRelatedMaturityReceivables	374894000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15490000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27367000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	437888000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	502074000
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	3912000
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	4942000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	108594000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	110020000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	64682000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	66069000
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15227000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15227000
CY2023Q1	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	0
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	7196000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33000
CY2023Q1	us-gaap	Assets Assets	630336000
CY2022Q4	us-gaap	Assets Assets	705561000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9855000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8265000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31513000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53932000
CY2023Q1	fate	Cirm Award Liability Current CIRMAwardLiabilityCurrent	0
CY2022Q4	fate	Cirm Award Liability Current CIRMAwardLiabilityCurrent	4000000
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1738000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	42226000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5545000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5628000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	48651000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	114051000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	102070000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	103710000
CY2023Q1	fate	Stock Price Appreciation Milestones Liabilities Non Current StockPriceAppreciationMilestonesLiabilitiesNonCurrent	2143000
CY2022Q4	fate	Stock Price Appreciation Milestones Liabilities Non Current StockPriceAppreciationMilestonesLiabilitiesNonCurrent	3861000
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98191015
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98191015
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97294917
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97294917
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	98000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	97000
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1547702000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1536497000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-646000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1854000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1069685000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1050804000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	477472000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	483939000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	630336000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	705561000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	58980000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18414000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65629000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72139000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21943000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20742000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	87572000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	92881000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28592000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-74467000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3694000
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	418000
CY2023Q1	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-1718000
CY2022Q1	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-8359000
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4299000
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9711000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8777000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18881000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-65690000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1208000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2088000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-17673000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-67778000
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98054687
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98054687
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96343529
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96343529
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-18881000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-65690000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4191000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2761000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10983000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19331000
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2295000
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-873000
CY2023Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	7196000
CY2022Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1094000
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-40488000
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3497000
CY2023Q1	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-1718000
CY2022Q1	fate	Increase Decrease In Fair Value Of Stock Price Appreciation Milestones IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones	-8359000
CY2023Q1	fate	Grant Income From Cirm Award GrantIncomeFromCirmAward	4000000
CY2022Q1	fate	Grant Income From Cirm Award GrantIncomeFromCirmAward	0
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-24980000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5174000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11901000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2407000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-20393000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3493000
CY2023Q1	fate	Increase Decrease In Right Of Use Assets And Lease Liabilities Net IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	-336000
CY2022Q1	fate	Increase Decrease In Right Of Use Assets And Lease Liabilities Net IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	-52000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28860000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64613000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3208000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10084000
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	114452000
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	132166000
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	127000000
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	135224000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18881000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7026000
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	207000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2797000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	207000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2797000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19313000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-68842000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	76560000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148810000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	57247000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79968000
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	612000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3377000
CY2023Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.60
CY2023Q1	fate	Restructuring And Related Cost Number Of Positions Retained RestructuringAndRelatedCostNumberOfPositionsRetained	220
CY2023Q1	us-gaap	Other Employee Related Liabilities Current And Noncurrent OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent	12900000
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	10900000
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000000.0
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s unaudited condensed consolidated financial statements relate to its stock price appreciation milestone obligations, contracts containing leases, and accrued expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42020000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64741000
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15227000
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15227000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	57247000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	79968000
CY2023Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	15200000
CY2022Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	15200000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29800000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-65700000
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27700000
CY2023Q1	fate	Expected Ressarch Services Period ExpectedRessarchServicesPeriod	P4Y
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	236754000
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	787000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	270967000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1899000
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2023Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2022Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2023Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y3M18D
CY2023Q1	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0
CY2022Q1	us-gaap	Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld	0
CY2023Q1	us-gaap	Share Price SharePrice	5.70
CY2023Q1	us-gaap	Share Price SharePrice	5.70
CY2023Q1	fate	Fairvalueassetslevel1 Tolevel2 Transfersamounts Fairvalueassetslevel1Tolevel2Transfersamounts	0
CY2023Q1	fate	Fairvalueassetslevel2 Tolevel1 Transfersamounts Fairvalueassetslevel2Tolevel1Transfersamounts	0
CY2023Q1	fate	Fairvalueliabilitieslevel1 Tolevel2 Transfersamounts Fairvalueliabilitieslevel1Tolevel2Transfersamounts	0
CY2023Q1	fate	Fairvalueliabilitieslevel2 Tolevel1 Transfersamounts Fairvalueliabilitieslevel2Tolevel1Transfersamounts	0
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6034000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	17899000
CY2023Q1	fate	Accrued Clinical Trial Related Costs Current AccruedClinicalTrialRelatedCostsCurrent	15250000
CY2022Q4	fate	Accrued Clinical Trial Related Costs Current AccruedClinicalTrialRelatedCostsCurrent	16858000
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10229000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19175000
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31513000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53932000
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0829
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	477472000
CY2023Q1	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	3318000
CY2022Q1	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	3815000
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	613000
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	618000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	3931000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4433000
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	10760000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	14648000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15087000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	15540000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	16006000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	15057000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	86580000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	173678000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	66063000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	107615000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	678838000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3001000
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1208000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10983000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19331000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	483939000
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	222000
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10983000
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19331000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2088000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-65690000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	633393000

Files In Submission

Name	View Source	Status
fate-20230331_cal.xml	Edgar Link	unprocessable
fate-20230331_lab.xml	Edgar Link	unprocessable
0000950170-23-017175-index-headers.html	Edgar Link	pending
0000950170-23-017175-index.html	Edgar Link	pending
0000950170-23-017175.txt	Edgar Link	pending
0000950170-23-017175-xbrl.zip	Edgar Link	pending
fate-20230331.htm	Edgar Link	pending
fate-20230331.xsd	Edgar Link	pending
fate-ex31_1.htm	Edgar Link	pending
fate-ex31_2.htm	Edgar Link	pending
fate-ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
fate-20230331_def.xml	Edgar Link	unprocessable
fate-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
fate-20230331_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FATE
Fate Therapeutics Inc Stock $fate

2023 Q2 Form 10-Q Financial Statement

#000095017023017175 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE Fate Therapeutics Inc Stock $fate

2023 Q2 Form 10-Q Financial Statement

#000095017023017175 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE
Fate Therapeutics Inc Stock $fate